Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
P/E ratio for Portage Biotech Inc. (PRTG)
P/E ratio as of 2024: -2.99
According to Portage Biotech Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.99. At the end of 2023 the company had a P/E ratio of -9.52.
P/E ratio history for Portage Biotech Inc. from 1998 to 2024
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2024 | -2.99 |
| 2023 | -9.52 |
| 2022 | -89.52 |
| 2021 | -381.84 |
| 2020 | -274.97 |
| 2019 | -343.88 |
| 2018 | 3.46 |
| 2017 | 59.23 |
| 2016 | -100.84 |
| 2015 | -148.88 |
| 2014 | -61.61 |
| 2013 | -197.82 |
| 2012 | -19.07 |
| 2011 | -32.77 |
| 2010 | -98.14 |
| 2009 | -109.41 |
| 2008 | -301.11 |
| 2007 | -1151.10 |
| 2006 | -43.83 |
| 2005 | -51.76 |
| 2004 | -134.21 |
| 2003 | -19.93 |
| 2002 | -33.14 |
| 2001 | -11.60 |
| 2000 | -232.68 |
| 1999 | -277.95 |
| 1998 | -16.71 |